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Background
Trimethoprim-sulfamethoxazole (TMP-SMX) is a broad
spectrum antimicrobial agent and also reduces the mor-
tality among adults and children when used as prophy-
laxis against opportunistic infections in HIV infected
patients. Drug resistant to TMP-SMX along with
Extended spectrum b-lactamase (ESBL) production
among Enterobacteriaceae is creating major therapeutic
problem in clinical settings for treating the bacterial
infections among HIV individuals.
Methods
TMP-SMX drug resistance among the isolates was identi-
fied using Kirby-Bauer disc diffusion method and ESBL
production by combination disc method (CDM). Cefotax-
ime (30µg) and cefotaxime/clavulanic acid (30μg/10μg)
discs were placed 20 mm apart on the agar surface. Simi-
larly, the ceftazidime (30µg) and ceftazidime/clavulanic
acid (30μg/10μg) discs were also placed. After incubating
overnight at 37°C, a ≥ 5mm increase in the zone diameter
was interpreted as positive for ESBL production. Statistical
analysis was done using SPSS software version 15.0.
Results
A total of 103(40 Escherichia coli, 15 Klebsiella pneumo-
niae, 13 Pseudomonas aeruginosa, 10 Klebsiella oxytoca, 8
Proteus mirabilis, 2 Proteus vulgaris, 11 Staphylococcus aur-
eus, 3 Staphylococcus epidermidis and 1 Streptococcus sp.)
bacterial strains were isolated from HIV patients. Among
these 65(63.10%;p=0.008) isolates were resistance to TMP-
SMX and only 40(38.83%;p=0.023) isolates were resistant to
extended spectrum b-lactam antibiotics. Twenty nine ESBL
producers from HIV patients were found to be co resistant
to TMP-SMX. All ESBL producing isolates showed resis-
tance to ceftazidime and also for ceftazidime/clavulanic
acid combination.
Conclusion
A rapid increase in the use of prophylactic TMP-SMX
might be responsible for the TMP-SMX drug resistance
among opportunistic bacterial infections in HIV patients.
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